Sigilon Therapeutics, Inc. (SGTX)
|Net Income (ttm)||-33.70M|
|Trading Day||January 19|
|Day's Range||33.38 - 36.32|
|52-Week Range||27.60 - 48.03|
Sigilon Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021
CAMBRIDGE, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its S...
Sigilon Therapeutics Receives Orphan Drug Designation for SIG-005 for the Treatment of Mucopolysaccharidosis Type I
Company plans to initiate a Phase 1/2 trial of SIG-005 in patients with mucopolysaccharidosis type I (MPS-1) in the second half of 2021 Company plans to initiate a Phase 1/2 trial of SIG-005 i...
Sigilon Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its S...
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for...
Cambridge, Massachusetts-based Sigilon was founded to develop its Shielded Living Therapeutics platform which uses advanced techniques to create therapeutic molecules for the treatment of rare...
Sigilon Therapeutics (SGTX) has filed a prospectus for a $100M IPO. The Cambridge, MA-based biotech develops cell therapies based on its Shielded Living Therapeutics (SLTx) platform that combi...
Sigilon Therapeutics, a clinical stage biotech developing molecular therapeutics for chronic diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Sigilon Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Sigilon Therapeutics, a biopharmaceutical company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. The company was formerly known as Sigilon, Inc... [Read more...]
|IPO Date |
Dec 4, 2020
Rogerio Vivaldi Coelho
|Stock Exchange |
|Ticker Symbol |
In 2019, SGTX's revenue was $14.16 million, an increase of 205.26% compared to the previous year's $4.64 million. Losses were -$43.93 million, 92.9% more than in 2018.
According to 4 analysts, the average rating for SGTX stock is "Buy." The 12-month stock price forecast is 53.75, which is an increase of 53.70% from the latest price.